Professor Gregory YH Lip MD, FRCP (London, Edinburgh, Glasgow), DFM, FACC, FESC

Professor Gregory YH Lip

Institute of Cardiovascular Sciences
Professor of Cardiovascular Medicine, University of Birmingham, UK
Adjunct Professor of Cardiovascular Sciences, Thrombosis Research Unit, Aalborg University, Denmark
National Institute for Health Research (NIHR) Senior Investigator

Contact details

Telephone
+44 (0) 121 5075080
Fax
+44 121 507 5503
Email
g.y.h.lip@bham.ac.uk
Address
University of Birmingham - Institute of Cardiovascular Sciences
City Hospital
Birmingham
B18 7QH

Professor Lip is a clinical researcher, with a major interest into the epidemiology of atrial fibrillation (AF), as well as the pathophysiology of thromboembolism in this arrhythmia.  Furthermore, he has been researching stroke and bleeding risk factors, and improvements in clinical risk stratification.  The CHA2DS2-VASc and HAS-BLED scores - for assessing stroke and bleeding risk, respectively – were first proposed and independently validated following his research, and are now incorporated into international guidelines. 

He was selected to the Thomson Reuters Science Watch list of ‘World’s Most Influential Scientific Minds 2014’, a ranking of today’s top 17 scholars who have published the greatest number of hot papers, ranked in the top 0.1% by citations, [issued June 2014; see website: http://archive.sciencewatch.com/].  In 2014, Professor Lip was ranked by Expertscape as the world's leading experts in the understanding and treatment of AF [http://bit.ly/2apB1Dt].  This global top ranking is still maintained in January 2018 [see http://expertscape.com/ex/atrial+fibrillation]

Professor Lip also works with multiple institutions both nationally and internationally:- 

  • Visiting Professor of Haemostasis Thrombosis & Vascular Sciences, Aston University, Birmingham, UK 
  • Visiting Professor of Cardiology, University of Belgrade, Serbia
  • Visiting Professor, University of Leeds, UK 
  • Honorary Professor, Chinese PLA Medical School, Beijing, China  
  • Honorary Professor, Nanjing Medical University, Nanjing, China
  • Visiting Professor, National Yang-Ming University, Taipei, Taiwan
  • Adjunct Professor, Yonsei University, Seoul, South Korea

Qualifications

University Education:  University of Glasgow, Glasgow, G12 8QQ. 

Graduated July 1988 with the degrees of M.B., Ch.B. (with commendation) with the following prizes for the most distinguished graduate in medicine and surgery of the year:

 - the BRUNTON MEMORIAL PRIZE and the Robert Fullerton Prize

MEMBERSHIP OF THE ROYAL COLLEGES OF PHYSICIANS  M.R.C.P.(U.K.) March 1991

DIPLOMA OF FORENSIC MEDICINE (DFM) with Class Prize. September 1993

DOCTOR OF MEDICINE (M.D.) University of Glasgow, September 1994

FELLOW OF THE AMERICAN COLLEGE OF CARDIOLOGY (F.A.C.C.) August 1996

FELLOW OF THE EUROPEAN SOCIETY OF CARDIOLOGY (F.E.S.C.) June 1997

FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH (F.R.C.P.Edin) Sept 1998

FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF GLASGOW (F.R.C.P.Glasg) 1999

FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON (F.R.C.P.Lond) May 2001

FELLOW OF THE EUROPEAN HEART RHYTHM SOCIETY (F.E.H.R.A.) December 2016

Honorary Doctorates

DOCTOR MEDICINAE HONORIS CAUSA Aalborg University, Denmark: April 2013

DOCTOR HONORIS CAUSA, University of Medicine & Pharmacy “Carol Davila”, Bucharest, Romania; September 2016

DOCTOR HONORIS CAUSA, Belgrade University, Republic of Serbia; October 2016

DOCTOR HONORIS CAUSA, i'Universite de Tours, France, conferred March 2017

Biography

Professor Lip, MD, is Professor of Cardiovascular Medicine at the University of Birmingham and is based in a busy city centre teaching hospital. He is also Adjunct Professor of Cardiovascular Sciences, Aalborg University, Denmark.

Half of his time is spent as a clinical cardiologist, and he practises the full range of cardiovascular medicine, including outpatient clinics (leading large atrial fibrillation and hypertension specialist services), interventional cardiology and coronary care unit.

Professor Lip has had a major interest into the epidemiology of atrial fibrillation (AF), as well as the pathophysiology of thromboembolism in this arrhythmia.  Furthermore, he has been researching stroke and bleeding risk factors, and improvements in clinical risk stratification.  The CHA2DS2-VASc and HAS-BLED scores - for assessing stroke and bleeding risk, respectively – were first proposed and independently validated following his research, and are now incorporated into international guidelines. 

He was selected to the Thomson Reuters Science Watch list of ‘World’s Most Influential Scientific Minds 2014’, a ranking of today’s top 17 scholars who have published the greatest number of hot papers, ranked in the top 0.1% by citations, [issued June 2014; see website: http://archive.sciencewatch.com/].  In 2014, Professor Lip was ranked by Expertscape as one of the world's leading experts in the understanding and treatment of AF [http://bit.ly/2apB1Dt].

His research is highly cited [h-index: 164 (i10-index 1414) with >194,000 citations (Google Scholar) as at 11 January 2018] and has been listed as a highly cited researcher since 2014, representing the top 1% most cited for their subject field [http://highlycited.com], representing the list of the world’s most influential scientists whose work has been consistently judged by their peers to be of particular significance, ie. being the top 1% most cited for their subject field and year of publication.

Professor Lip is a board member of the European Heart Rhythm Association (EHRA) and is Chairman of its scientific documents committee (2013-).    

Professor Lip was on the writing committee for various international guidelines, including the American College of Chest Physicians (ACCP) Antithrombotic Therapy Guidelines for Atrial Fibrillation, as well as various guidelines and/or position statements from the European Society of Cardiology (ESC) or EHRA. Specifically, he was also on the writing committees of the 2010 ESC Guidelines on Atrial Fibrillation, the 2012 ESC Focused Update Guidelines on Atrial Fibrillation, the 2012 ESC Guidelines on Heart Failure, and the 2014 NICE guidelines on AF.  He was Deputy Editor (“content expert”) for the 9th ACCP guidelines on antithrombotic therapy for AF (2012). 

Professor Lip has acted as senior/section editor for major international textbooks and at senior editorial level for major international journals, including Thrombosis & Haemostasis (Editor-in-Chief, Clinical Studies); Europace (Associate Editor); and Circulation (Guest Editor).

Postgraduate supervision

Academic supervision and training:  I have successfully supervised ~45 awarded higher degrees (MD/PhD/MPhil) since 1997 [12 theses since 2012].  I am currently supervising 6 students, with ongoing research or awaiting thesis submission.

I have established a global research training network providing new insights for multi-ethnic Birmingham.  I regularly host & supervise overseas research fellows, incl. China, Japan, Poland, Italy, Spain, South Korea, etc. Supervisees have returned to academic positions (including 4 Professors) in overseas countries.    

Research

Recent highlights   

  • My research work has delivered crucial impacts in changing national and international clinical practice guidelines and improvements in patient care within three principal areas: (i) treatment decisions related to stroke and bleeding risk in atrial fibrillation (AF), which is the commonest cardiac arrhythmia in the general population, (ii) screening practice in primary care, and (iii) stroke and bleeding risk assessment. These ultimately lead to reduced morbidity and mortality for a significant proportion of the population, particularly among the elderly.

My research impact on improvements in healthcare is summarised in a University of Birmingham 2014 Research Excellence Framework (REF) Impact Case Study: http://impact.ref.ac.uk/CaseStudies/CaseStudy.aspx?Id=38790

  • I was selected to the Thomson Reuters Science Watch list of ‘World’s Most Influential Scientific Minds 2014’, a ranking of today’s top global 17 scholars who have published the greatest number of hot papers, ranked in the top 0.1% by citations, [issued June 2014; see website: http://sciencewatch.com/sites/sw/files/sw-article/media/worlds-most-influential-scientific-minds-2014.pdf].  In 2013, I was also selected to the Thomson Reuters Science Watch list of “Who and What was Hot in Scientific Reseach in 2012” (issued June 2013) which lists the most influential scientific researchers and research papers of the year.  See http://sciencewatch.com/articles/hottest-research-2012.    
  • I am listed as Highly Cited Researcher [2014, 2015, 2016, 2017], representing the top 1% most cited for their subject field [http://highlycited.com], representing the list of the world’s most influential scientists whose work has been consistently judged by their peers to be of particular significance, ie. being the top 1% most cited for their subject field and year of publication.
  • October 2016: SWBH ‘Trust Beacon Service award’ for Cardiology, as ‘an internationally-recognised centre for atrial fibrillation’, and SWBH ‘Excellence in Research’ award for my Atrial Fibrillation research team, which topped the SWBH league table in 2015-16 in terms of numbers of patients recruited to research studies on the NIHR portfolio, as well as major contributions to the delivery of the Trust’s R&D plan including enhanced integration with primary care and the translation of research into better and safer clinical care.
  • I was recently awarded National Institute for Health Research (NIHR) Senior Investigator status (2017-2020) in open competition.
  • In January 2014, I was ranked by Expertscape as the world's leading expert in the understanding and treatment of AF, and correspondingly, the University of Birmingham listed as the world's top institution for AF research [See http://www.prlog.org/12273752-expertscape-ranks-top-doctors-and-hospitals-in-atrial-fibrillation.html].  My global top ranking is still maintained in September 2017 [see http://expertscape.com/ex/atrial+fibrillation]     
  • In June 2014, ranked by Expertscape as amongst the world's leading expert in the understanding and treatment of Hypertension [See http://www.prlog.org/12327635-expertscape-ranks-worlds-top-doctors-and-hospitals-in-hypertension.html]
  • My work into improving AF clinical management won the Heart Rhythm UK ‘Arrhythmia Alliance Team of the Year Award 2012'(http://www.heartrhythmcongress.com/archive-folder/HRC%20_2012_Excellence_Awards.html) and the BMJ Group ‘Cardiovascular Team of the Year 2013’ award 
  • I received the 2016 National Institute for Health Research (NIHR) CRN West Midlands Clinical Research Impact award; for atrial fibrillation research, September 2016
  • July 2017, West Midlands Academic Health Sciences Network Celebration of Innovation ‘Excellence in Wellness and Prevention Award’ Winner for “Birmingham 3 step approach” Prof GYH Lip/Dr S Sarwar: University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust. 

1.  With regard to clinical management, clinical risk scores developed and validated by my work to assess stroke & bleeding risk in atrial fibrillation (AF) (ie. CHA2DS2-VASc & HAS-BLED) are used in national/international management guidelines, eg. UK National Institute for Health & Care Excellence (NICE, 2006 & 2014), European Society of Cardiology (ESC 2012, 2016), Canadian Cardiovascular Society (2012), Asia Pacific Heart Rhythm Society (APHRS 2013, 2017), American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines (2014) etc. The CHA2DS2-VASc score helps clinicians formally assess stroke risk and identify `truly low risk' patients who do not need antithrombotic therapy, and effectively captures those patients who should be considered for stroke prevention. Risk assessment with CHA2DS2-VASc is part of the NICE Quality Outcomes Framework (QOF) and is easily available for use by GPs as part of the Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) risk stratification tool, which is freely available and compatible for use with all GP clinical systems in England. The simple, user-friendly HAS-BLED score, comprising risk factors either readily available from the clinical medical history or routinely tested in (new) patients, allows clinicians to formally assess bleeding risk, focusing on modifiable risk factors (optimising blood pressure control, removing concomitant anti-platelets, reducing alcohol intake, and optimising time in therapeutic range for those taking warfarin), and those who require regular review (patients at higher bleeding risk).  The impact on implementing these risk scores into AF populations Europe-wide could potentially prevent >60000 major cardiovascular events & deaths each year amongst AF patients with a CHA2DS2-VASc ≥2 (Thromb Haemost 2013;109:328).

My development of SAMe-TT2R2 score (2013) aids decision-making between warfarin and new anticoagulants.  This score is incorporated into ESC/NICE consensus recommendations, Clinical Commissioning Group (CCG) for AF (2014) and the PRIMIS Warfarin Patient Safety audit tool (2014).  The CHA2DS2-VASc, HAS-BLED and the SAMe-TT2R2 scores are now part of the CCG AF patient pathway streamlining decision making and improving the primary-secondary care interface (the ‘Birmingham 3-step’ AF pathway, 2016). The latter forms the basis of the West Midland Academic Health Science Network (AHSN) ‘Preventing AF related Strokes’ initiative (2017).

My overall clinical research work into AF has also had a major impact on recommendations in AF guidelines issued by NICE (2006 and 2014), as well as the ESC (2010, 2012 and 2016), CCS (2011) and ACCP (2012). My research has informed European consensus guidelines on the optimal management of anticoagulated AF patients who present with an acute coronary syndrome ± undergo coronary intervention/stenting (ESC, 2010 and 2014), as well as the assessment/management of bleeding in AF patients (European Heart Rhythm Association (EHRA), 2011).

2.  The concept of ‘atrial fibrillation is a prothrombotic or hypercoagulable state’ was first proposed by myself in a Lancet article in 1996.  My ongoing work has validated biomarkers of thromboembolism and vascular biology in cardiovascular disease (esp AF) as prognostic indices, and such biomarkers have been used in the assessment and investigation of AF, and the study of new antithrombotic drugs by industry (various ongoing studies, 2009-), as surrogate biomarkers of clot formation in AF.

3.  Since 2009, my research group has ongoing research collaborations nationally (Aston University, Birmingham; London; Leeds) and internationally (Copenhagen and Aalborg Universities, Denmark; University of Murcia, Spain; University of Iowa, USA; Fushimi Community AF registry, Japan; University of Belgrade, Serbia; University of Tours, France; University of Hong Kong; Beijing, Nanjing and Guangzhou, China; National Yang-Ming University, Taipei, Taiwan; University of Lodz, Poland).  

My international network of collaborators has allowed me to pursue to strategy of research globalisation & the study of culture/ethnic/country-specific issues, particularly cardiovascular conditions esp. in AF.  This has led to numerous key publications, addressing global aspect of AF epidemiology & implications for healthcare systems in emerging economies.

I currently have joint programme grants with the University of London (BHF/Stroke Association – CROMIS-2 study, c£1m; 2010-ongoing; European Union H2020 programme, PRESTIGE-AF, Euro 9m, 20117-ongoing); Leeds (Wellcome Trust, £3m; 2015- ongoing) and Aalborg University, Denmark (Danish National Research Council – epidemiology and pathophysiology of AF, c£2.5m; 2010-ongoing).  I am part of the Lipid, Blood Pressure Meta-analysis Collaboration (LBPMC) Group and Health Aging Research Center (HARC) funded by European Union FP7 Funding (FP7-REGPOT-2012-2013-1), based at University of Lodz, Poland. The latter collaboration is recently extended with EU funding for the LIPIDOGRAM2015 & LIPIDOGEN2015 studies.

Overall, I have successfully attracted major grant funding (total £20+ million cumulative) from the British Heart Foundation, Heart Research UK, Medical Research Council, NHS HTA Programme, Arthritis Research Council, Action Medical Research, Peel Medical Research Trust, etc). I have acted as principal investigator for various projects in my department and successfully supervised/co-supervised approximately 45 postgraduate theses, leading to MD, PhD, Masters, etc higher degrees. 

4. I have regular invitations to deliver Keynote/plenary lectures at International/Major National Meetings, often delivering the Opening Ceremony inaugural lecture, or Named Lecture at major congresses.  Some recent examples (selected) as follows:

  • Bradshaw Lecturer for the Royal College of Physicians of London, in November 2013: (See http://en.wikipedia.org/wiki/Bradshaw_Lecture)
  • March 2014, appointed Visiting Professor and delivered the annual Razavi Lecture at the Cleveland Clinic Medical School,      Cleveland, USA.   
  • March 2014, appointed Wu Chung Visiting Professor and lecturer at the University of Hong Kong
  • May 2014, Special Grand Rounds Visiting Lecturer at Columbia University, New York, USA.      
  • September 2014, awarded the Polish Cardiac Society medal, and gave the Inaugral Opening Lecture at the XVIII Congress of the Polish Cardiac Society, in Poznan, Poland.
  • January 2015, delivered the Sun Chieh Yeh Heart Foundation Lecture at the Opening Ceremony of the Cardiorhythm 2015 meeting in Hong Kong.
  • April 2015, delivered the Michaelides lecture, at the 30th International Meeting on Clinical Cardiology, organized by the Hellenic Heart Foundation; Athens, Greece
  • October 2015, Opening Ceremony lecture 26th Great Wall International Congress of Cardiology (GW-ICC) & Asia Pacific Heart Congress 2015 & International Congress Cardiovascular Prevention and Rehabilitation 2015 
  • November 2016, Key Note Speaker at National Institute for Preventive Cardiology of Ireland - National Prevention Meeting (www.nipc.ie) in Galway, Ireland.
  • December 2016, Opening Ceremony Lecture at the Icelandic Society of Internal Medicine Congress, Reykjavik.
  • February 2017:  Closing Ceremony Plenary Lecture, at 61st Annual Meeting of the Society of Thrombosis and Hemostasis Research (GTH), Basel, Switzerland, February 15th – 18th2017.
  • September 2017, Polish Cardiac Society medal and awarded honorary membership of the society.  XXI International Congress of the Polish Cardiac Society - Katowice, Poland.
  • May 2015, delivered the Founders Lecture at the Heart Rhythm Society meeting (the world’s largest arrhythmia meeting) in Boston, USA
  • June 2015, delivered the Opening Ceremony Plenary Lecture at the Norweigian Cardiac Society meeting, Tromso, Norway
  • September 2015, delivered the Opening Ceremony Inaugural Lecture at the Romanian Congress of Cardiology meeting, Sinaia, Romania (September 2015) and conferred honorary membership of the Romanian Society of Cardiology.

 

  • March 2016, Opening Plenary guest lecturer:  Dutch Cardiology Society Conference, Noordwijkerhout, The Netherlands
  • April 2016, Opening Plenary ‘State of the Art’ Lecture, National Heart Association of Malaysia  
  • May 2016, Hungarian Society of Cardiology medal, Opening ceremony and Honorary Membership lecture, Annual Scientific Congress of the Hungarian Society of Cardiology, Balatonfüred
  • June 2016, Cardiostim-EHRA Europace 2016 Opening Ceremony ‘State of the (he)Art’ lecture ‘Stroke and bleeding risk in      atrial fibrillation: evidence, guidelines and clinical practice.’
  • June 2016:  Martin Green Lecture, Ottawa Heart Research Conference 2016: Translational Research in Atrial Fibrillation
  • October 2016: Prof. Chudomir Nachev Lecture, at the 15th Bulgarian National Congress of Cardiology, Sofia, Bulgaria

 

 

I have regularly been invited to organise and/or deliver masterclasses and practice-based symposia at national and international meetings on AF and/or thrombosis.  I have been involved (expert speaker, or workshop lead) in ESC regulatory and implementation workshops for the ESC/EHRA and NICE.  I have been co-organiser for the German Atrial Fibrillation Competence NETwork/EHRA consensus conferences (biannually, since 2010), which have defined clinical practice in their respective areas.

6.  Engagement with industry and translational research:  I have had significant engagement with industry, especially in areas related to AF and thrombosis, acting as steering committee or Chairman of multicentre, international studies.  In addition, I have worked on translational scientists in new drug developments, leading to partnerships between academia (eg. Universities of Aston, Birmingham, Leeds etc). Some recent examples (selected) as follows:

  • Steering Committee Chair on various multicentre clinical trials that bring research from industry to the UK. These include various Phase II trials with new anticoagulants (eg. AZD0837, see PubMed PMID: 19690349) and Phase III international trials (eg. ENSURE-AF, PMID: 25965706), and registries (eg. GLORIA-AF, PMID: 26239094; PMID: 24576516). I have also acted as UK lead investigator for international trials, with representation on trial steering committees (eg. PIONEER-AF, see PMID: 25819853)
  • My translational work on AF as a prothrombotic or hypercoagulable state as validated biomarkers of thromboembolism in AF (Lancet. 2009;373:155-66). These biomarkers are used in industry trials as surrogate biomarkers of clot formation in AF, eg. for characterisation of the direct thrombin inhibitor AZD0837 (see PMID: 26174611).  We have recently focused on      AF and renal impairment, assessing clot structure and function (PMID: 27356648), with a view to new therapeutic interventions for such patients.
  • I have worked with translational scientists in new drug development, leading to a recent Wellcome Trust Seeding Drug Discovery Award in 2015 (‘Lead identification of a novel anticoagulant agent targeting activated factor XII for the prevention of thrombosis with minimal risk of bleeding; £3m). These include funding for basic scientists and addressing the unmet clinical needs of new anticoagulants, bridging bench to bedside.       
  • Current translational research partnerships ongoing with Aston University in collaboration with life sciences for early and exploratory development of new drugs to modulate cardiac fibrosis (grant applications in process)
  • Other engagement includes contract research with the life sciences industry, including testing novel diagnostic biomarkers, eg. free light chains quantification in cardiovascular disease with the Binding Site PLC (see PMID: 25260814; PMID: 25828674)
  • Given my interests in clinical epidemiology and outcomes research, I have led various 'real world' registries, as well as health economic analyses and outcomes research independently or industry-sponsored (see PMID: 26316345; PMID: 26477648). Some have been used to inform NICE cost-effectiveness models and appraisals, allowing the NHS and public sector to make informed decisions with efficient use of resources.

Other activities

Academic evaluation and assessment:  I regularly act as evaluator for academic promotion applicants of national/international universities [multiple times eg. Hong Kong, Amsterdam, Athens, Israel (all 2012-)]. I was part of international expert panel for Heart & Stroke Foundation Canada endowed Chair renewal committee (2015).

I regularly act as examiner, nationally/internationally (under/postgraduate exams), a eg. Vienna (2013), Pisa (2014), Adelaide (2014), London (2016) I am a regular peer review for research grants from national/international funders, including research councils from various countries.  I have been part of external peer review evaluation panels for research funding awards, with site evaluation visits to Mainz (2012) and Leuven (2016).

Other teaching and education initiatives:  I led the development of the European Heart Rhythm Association(EHRA) AF patient education website [www.afibmatters.org]. Since 2013, translated into French/German/Spanish/Italian versions.

AF patient counselling/education methodology from my TREAT trial [PMID: 24040156] has been implemented into outpatient clinical services, & adopted by other units. This approach is ‘good practice example’ in NICE NOAC (new anticoagulants) Implementation Consensus (2014).  With US collaborators, I helped develop an education/decision support tool, AF Guideline Support Tool (AFGuST), which improves quality-adjusted life expectancy for a primary care AF population [PMID:25205788]. This patient-tailored tool bridges the gap between guidelines & practice, facilitating shared decision making, with good results (PMID:25690491).  Ongoing research now focuses on NHS implementation. Locally, I have been supporting GP leads from Clinical Commissioning Groups in disseminating programmes for bridging primary-secondary care AF management (2015-).  This integrates of primary-secondary care management pathways, esp. new anticoagulants for AF and venous thromboembolism with CCGs and Trust (2015). I have also been conducting up-skilling programme for local GPs on AF, in close collabotations with Clinical Commissioning Groups (2015-). 

Miscellaneous:  I have advised/written for UpToDate [popular resource for teaching/education, updated 3x/year], Oxford Textbook of Medicine (AF and Hypertension chapters, 5th ed. 2015, includes MCQs) and ESC Textbook of Cardiovascular Medicine (Part of ESC core curriculum for European cardiologists – section lead, for new edition 2016) I have advised and written for BMJ Point of Care (2010-), and the Royal College of Physicians Map of Medicine (2010-).  

ACADEMIC CITIZENSHIP  

Recent highlights

  • I have been conferred four honorary doctorate degrees - doctor medicinae honoris causa from Aalborg University, Denmark (http://bit.ly/2fGyIfC); University of Medicine & Pharmacy “Carol Davila”, Bucharest, Romania (http://bit.ly/2f2yY7p); Belgrade University, Serbia; and i'Universite de Tours, France
  • Appointed as Chairman of the Writing Group of the new international American College of Chest Physicians (ACCP Guidelines on Antithrombotic therapy for AF (10th edition, 2016-), the first non-US chairman of these guidelines.       Previously served as writing committee member for the 8th and 9th ACCP guideline editions. For the 9th ACCP guideline (2012), I was appointed as ‘content expert’ (ie. ’deputy editor’) for the AF guideline chapter.
  • European Society of Cardiology and European Heart Rhythm Association (EHRA):  Chairman (2011-2015; and still      remain on Executive Steering Committee, as ‘Past Chairman’ 2016-) of the European Society of Cardiology      (ESC) EuroObservational Research Programme on Atrial Fibrillation (EORP-AF), defining the epidemiology and management of AF in Europe.  I have also managed and developed international registry collaborations with ESC/non-ESC countries (Asia-Pacific HRS, Japan, China, Serbia, Iran) as part of the INTER-AF collaboration (see PMID: 27806965). I am a member of the INTER-AF steering committee, which is an American College of Cardiology-led collaboration of academics      developing AF registry dataset harmonisation and inter-regional comparisons.

Since 2012, I have chaired 6 ESC/European Heart Rhythm Association (EHRA) consensus guidelines eg. Arrhythmias in AF with Heart failure (2015); AF with Acute coronary syndrome/Stenting (2014); valvular AF, hypertension (2016-2017).

Member, ESC Clinical Practice Guideline Committee (2014-2016); my work included implementation recommendations, self-testing modules & assessment of quality/audit standards. Peer reviewer of 8 ESC guidelines since 2012. Review Coordinator, 2015 ESC ventricular arrhythmia guidelines.

2015-2017, EHRA Board member/Chair, Scientific Documents Committee, coordinated new guideline development/reviews & facilitated implementation/education. In 2017 was appointed to the EHRA Governing Board as ‘Research Pillar’ Chairman, responsible for scientific initiatives/innovation and scientific documents. In 2014-2015, Chaired group developing EHRA AF patient education website (afibmatters.org) & translation into multilanguages

National Institute for Health and Care Excellence (NICE):  External expert and co-author for the NICE AF Quality Standards (2015): helped defined standards/benchmarking & co-author (2015). I was co-author, NICE Patient Pathways to accompany AF guideline & NICE NOAC Implementation Consensus (2014). I am an Expert Adviser for NICE Centre for Clinical Practice (including NICE Medicines & Prescribing Centre; 2016-). Clinical adviser to the UK NICE guidelines on atrial fibrillation (2006) and the subsequent NICE implementation/commissioning committee on anticoagulation for AF (2007).  I was the clinical expert to NICE, also representing the British Cardiovascular Society, on its evaluation of dabigatran (2011) and apixaban (2013) for stroke prevention in AF (2011).  I was on the Guideline Development Group      for the latest UK NICE guidelines on atrial fibrillation (2014), and part of the NICE Guideline surveillence review for AF (2016-2017).

Appointed to SIGN (Scottish Intercollegiate Guidelines Network (2016-) producing healthcare guidelines/service standards for NHS Scotland.

National Institute for Health Research (NIHR):  I was independent chairman of trial steering committee for NIHR Research for Patient Benefit-funded randomised trial: Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT) (PMID:26314489); I am a regular contributor of commentaries to NIHR Dissemination Centre and a regular peer reviewer of NIHR grants and study reports for NIHR Journals Library.  I am principal investigator of the NIHR EME-funded IMPRESS-AF trial, and co-applicant for ongoing NIHR-funded Research for Patient Benefit randomised trial (CBT-AF) which investigates cognitive behavioural therapy & education/counselling to improve outcomes in AF (2015-).  Currently member of NIHR College of Senior Investigators (2017-).

Grant review panels: Welcome Trust; Research Councils of Hong Kong/Sweden/Netherlands/Singapore; Ontario Research Fund; Canadian Institutes of Health Research. Chairman of grants evaluation panel, Research Council for Norway (2014).  Chairman, ERISTA grants programme award committee (2015-2016): annual chairing international expert committee, coordinating reviews & assessment/evaluation of research proposals. I am part of a multinational expert research evaluation committee for Leuven University (2016). Regular evaluation for academic promotion applicants from national/international universities [eg. Hong Kong, Amsterdam, Athens, Israel; Johns Hopkins Baltimore (USA), Singapore, etc (2012-)]. Part of international expert panel for Heart & Stroke Foundation Canada endowed Chair renewal committee (2015)

I currently serve as data safety management board (DSMB member for a Canadian Institutes for Health Research (CIHR) funded trial – BRUISE/BRUISE2 (2009-ongoing). 

External expert reviewer, 2016 Taiwan Society of Cardiology and Taiwan Heart Rhythm Society joint guidelines on AF      management.  Expert external reviewer for 2017 Asia-Pacific Heart Rhythm Society AF guidelines (2017).

I was part of a BMJ Writing group (2013) for NHS Shared Decision Making in the development of a patient decision aid for stroke prevention for AF or atrial flutter [http://sdm.rightcare.nhs.uk/pda/stroke-prevention-for-atrial-fibrillation

I am member of Council, Royal College of Physicians of Edinburgh (2015-) and have acted as West Midlands Regional Adviser for the RCPE (2013-).

In 2009, I was appointed Visiting Professor in Aston University, Birmingham.  In 2011, I was conferred the title of Adjunct Professor in Aalborg University, Denmark – for research and teaching.  I also hold Visiting Chairs in Belgrade, Beijing, Leeds, Taiwan, China, etc – primarily for research leadership.

As mentioned above, I have Chaired various task forces for the European Society of Cardiology, European Heart Rhythm Association (EHRA) and European Heart Failure Association, and was on various national/international guideline writing committees. I recently served on the scientific documents committee (2009-2011) and scientific initiatives committed (2011-2013) of EHRA.  From 2013, I have been appointed to the EHRA Board, as Chairman of the Scientific Documents Committee (2013-).  I am a writing committee member of an ESC Working Group on Thrombosis task force on Anticoagulants (2011-ongoing), producing a series of expert reviews and consensus documents on the use of anticoagulants in heart disease.  I was Chair of a EHRA Task Force that developed the EHRA patient information website for AF (2013, see www.afibmatters.org).

I am currently on the congress programme committee for the ESC congress (the world’s largest cardiology conress, 2016-), as well as Cardiostim and EHRA-Europace meetings (2011-), both being the major scientific meetings of EHRA.  I was Chair of the organisation and programme committee for the Royal College of Physicians of Edinburgh Consensus Conference on Atrial Fibrillation, March 2012.

I was invited as an ‘international technical expert’ in a Duke University Evidence-based Practice Center report "Stroke Prevention in Atrial Fibrillation", in partnership with the Agency for Healthcare Research and Quality (AHRQ) (USA, 2011-12).  I was a contributor to the US-led Antiplatelet- Academic Research Consortium (ARC) initiative (2015).

I was cardiovascular lead for the Birmingham and Black Country Comprehensive Local Research Network (BBC CLRN) from 2010-2011.  I was appointed UK Chief Investigator for 2 major non-industry academic multinational projects – the National Institutes for Health NINDS [cooperative agreements U01 NS43975 and U01 NS39143], USA, for WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) study (2010-), and more recently, the Netherlands Heart Foundation funded RACE-3 trial (Routine vs Aggressive Upstream rhythm control for prevention of early atrial fibrillation in heart failure; 2011-).

I am on the expert medical advisory committee (with other international experts on AF) for 2 major international patient organisations involved in atrial fibrillation – the AF Association (http://www.atrialfibrillation.org.uk) and Stopafib.org (http://stopafib.org) (both 2009-). 

Editorial leadership:  I am Editor in Chief (Clinical Studies) [2010-] of ‘Thrombosis & Haemostasis’ (2016 Impact factor 5.627).  Also regular Guest Editor for ‘Circulation’ (2009-).  I am an Associate Editor for ‘Europace’ (the main journal for the European Heart Rhythm Association; 2009-).  I am on the editorial boards of many of the main journals in the field, including the following (all with Impact Factor >4.0):  Journal of the American College of Cardiology, European Heart Journal, Circulation, Atherosclerosis Thrombosis & Vascular Biology, Heart, American Journal of Cardiology, American Heart Journal, Chest, American Journal of Medicine, etc.

Publications

h-index: 164 (i10-index 1414) with >194,000 citations (Google Scholar) as at 11 January 2018:-

Nielsen PB, Larsen TB, Skjøth F, Lip GY. Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. JAMA Intern Med. 2017 Feb 20. doi: 10.1001/jamainternmed.2016.9369.

Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY*, Larsen TB*. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017 Feb 10;356:j510. doi: 10.1136/bmj.j510  [*joint senior authors].

Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin  JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY; GLORIA-AF Investigators. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017 Feb 21;69(7):777-785.

Paquette M, Riou França L, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Huisman MV*, Lip GYH*, Nieuwlaat R*. Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017 Sep 26;70(13):1573-1583 [*joint senior authors].

Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016 Jun 16;353:i3189. doi: 10.1136/bmj.i3189.

Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY.  Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016 Aug 26. pii: S0140-6736(16)31474-X. doi: 10.1016/S0140-6736(16)31474-X.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17 [Original description of CHA2DS2-VASc score, cited >3100 times].

Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100 [Original description of HAS-BLED score, cited >2800 times]

Expertise

Cardiovascular Medicine